We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ALX Oncology Holdings Inc. (ALXO - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ALX Oncology Holdings Inc. is a member of the Medical sector. This group includes 914 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ALX Oncology Holdings Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ALXO's full-year earnings has moved 7.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ALXO has moved about 82.3% on a year-to-date basis. In comparison, Medical companies have returned an average of 3.5%. This means that ALX Oncology Holdings Inc. is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Medpace (MEDP - Free Report) . The stock is up 7.3% year-to-date.
Over the past three months, Medpace's consensus EPS estimate for the current year has increased 2.9%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, ALX Oncology Holdings Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 439 individual stocks and currently sits at #152 in the Zacks Industry Rank. On average, this group has gained an average of 6% so far this year, meaning that ALXO is performing better in terms of year-to-date returns.
In contrast, Medpace falls under the Medical Services industry. Currently, this industry has 72 stocks and is ranked #88. Since the beginning of the year, the industry has moved +2.1%.
Investors with an interest in Medical stocks should continue to track ALX Oncology Holdings Inc. and Medpace. These stocks will be looking to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ALX Oncology Holdings Inc. (ALXO - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ALX Oncology Holdings Inc. is a member of the Medical sector. This group includes 914 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ALX Oncology Holdings Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ALXO's full-year earnings has moved 7.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ALXO has moved about 82.3% on a year-to-date basis. In comparison, Medical companies have returned an average of 3.5%. This means that ALX Oncology Holdings Inc. is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Medpace (MEDP - Free Report) . The stock is up 7.3% year-to-date.
Over the past three months, Medpace's consensus EPS estimate for the current year has increased 2.9%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, ALX Oncology Holdings Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 439 individual stocks and currently sits at #152 in the Zacks Industry Rank. On average, this group has gained an average of 6% so far this year, meaning that ALXO is performing better in terms of year-to-date returns.
In contrast, Medpace falls under the Medical Services industry. Currently, this industry has 72 stocks and is ranked #88. Since the beginning of the year, the industry has moved +2.1%.
Investors with an interest in Medical stocks should continue to track ALX Oncology Holdings Inc. and Medpace. These stocks will be looking to continue their solid performance.